Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.355
+0.015 (1.12%)
Oct 28, 2025, 12:22 PM EDT - Market open
Outlook Therapeutics Revenue
Outlook Therapeutics had revenue of $1.51M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $1.51M.
Revenue (ttm)
$1.51M
Revenue Growth
n/a
P/S Ratio
25.75
Revenue / Employee
$65,449
Employees
23
Market Cap
60.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | - | - | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
OTLK News
- 4 weeks ago - Outlook Therapeutics Provides Update on Type A Meeting with FDA - GlobeNewsWire
- 7 weeks ago - Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - GlobeNewsWire
- 2 months ago - Outlook Therapeutics Requests Type A Meeting with FDA - GlobeNewsWire
- 2 months ago - Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug - Invezz
- 2 months ago - FDA Rejects Outlook Therapeutics Eye Drug For Second Time - Benzinga
- 2 months ago - US FDA declines to approve Outlook Therapeutics' drug for eye condition - Reuters
- 2 months ago - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD - GlobeNewsWire
- 2 months ago - Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision - Seeking Alpha